3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Wilms Tumor
2
Sarcoma, Ewing
2
Sarcoma
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Medulloblastoma
2
Lymphoma, Non-Hodgkin
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Glioma
2
Ependymoma
2
Xanthogranuloma, Juvenile
1
Thyroid Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Pheochromocytoma
1
Melanoma
1
Histiocytic Sarcoma
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Central Nervous System Neoplasms
1
Interventions
pembrolizumab
7
Nivolumab
6
enfortumab vedotin
5
Specimen Handling
5
Magnetic Resonance Spectroscopy
5
Ipilimumab
4
sacituzumab govitecan
3
Gemcitabine
3
Docetaxel
3
CTLA-4 Antigen
3
cabozantinib
2
Taxes
2
Paclitaxel
2
Cisplatin
2
Carboplatin
2
temsirolimus
1
relatlimab
1
lenvatinib
1
eribulin
1
avelumab
1
atezolizumab
1
Valproic Acid
1
Sirolimus
1
Single Person
1
Radiosurgery
1
Platinum
1
Immunoglobulin G
1
Disulfides
1
Cetuximab
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
tipifarnib
×
30 days
×
Clear all
No trials found.